Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2024-201850

Published: 2024

Journal Articles

Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia

Filip Matthijssens, Yoshitaka Miyakawa, Kaichi Nishiwaki, Jaume Ayguasanosa, Lan Lan, Anna Hultberg, Peter Ulrichts

Blood (2024) 144 (Supplement 1): 5443.

https://doi.org/10.1182/blood-2024-206889

Published: 2024

Journal Articles

Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2024-201328

Published: 2024

Journal Articles

Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma

Kohei Sato, Kazuhito Suzuki, Riku Nagao, Tadahiro Gunji, Masaharu Kawashima, Hideki Uryu, Mamiko Momoki, Hiroto Ishii, Mitsuji Katori, Susumu Tanoue, Atsushi Katsube, Hiroki Yokoyama, Takeshi Saito, Kaichi Nishiwaki, Shingo Yano

Blood (2024) 144 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2024-203587

Published: 2024

Journal Articles

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients

Mamiko Momoki, Atsushi Katsube, Masaharu Kawashima, Kazuhito Suzuki, Ryoko Fukushima, Tadahiro Gunji, Hiroto Ishii, Hideki Uryu, Kaichi Nishiwaki, Shingo Yano

Blood (2023) 142 (Supplement 1): 7063.

https://doi.org/10.1182/blood-2023-178631

Published: 2023

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Kazuhito Suzuki, MD, Kaichi Nishiwaki, MD, Tadahiro Gunji, MD, Mitsuji Katori, MD, Rika Hosoba, MD, Kei Hirano, MD, Hidekazu Masuoka, Shingo Yano, MD PhD

Blood (2018) 132 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2018-99-114822

Published: 2018

Journal Articles

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Kaichi Nishiwaki, MD PhD, Kei-Ji Sugimoto, MD PhD, Shigehisa Tamaki, MD PhD, Junichi Hisatake, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Atsushi Shinagawa, MD PhD, Takeaki Sugawara, MD PhD, Satoru Hara, MD PhD, Kazuhisa Fujikawa, MD PhD, Seiichi Shimizu, MD PhD, Yujiri Toshiaki, MD PhD, Arinobu Tojo, MD PhD, Hisashi Wakita, MD PhD

Blood (2016) 128 (22): 1925.

https://doi.org/10.1182/blood.V128.22.1925.1925

Published: 2016

Journal Articles

Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR 4.5 : Subgroup Analysis from STAT2 Trial in Japan

Naoto Takahashi, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD PhD, Hisashi Wakita, MD PhD

Blood (2016) 128 (22): 1889.

https://doi.org/10.1182/blood.V128.22.1889.1889

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Chiaki Nakaseko, MD PhD, Naoto Takahashi, MD PhD FJSIM, Kaichi Nishiwaki, MD PhD, Hitoshi Ogasawara, MD PhD, Hisashi Wakita, MD

Blood (2015) 126 (23): 4032.

https://doi.org/10.1182/blood.V126.23.4032.4032

Published: 2015

Journal Articles

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Blood (2014) 124 (21): 4870.

https://doi.org/10.1182/blood.V124.21.4870.4870

Published: 2014

Journal Articles

Impact of Ph+ Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study

Mayuko Tsuda, MD, Kaichi Nishiwaki, MD PhD, Kei-ji Sugimoto, MD PhD, Hisayuki Yokoyama, MD PhD, Tadahiko Igarashi, MD PhD, Seiichi Shimizu, MD PhD, Toshiaki Yujiri, MD PhD, Hisashi Wakita, MD PhD, Arinobu Tojo, MD PhD

Blood (2014) 124 (21): 3159.

https://doi.org/10.1182/blood.V124.21.3159.3159

Published: 2014

Journal Articles

Impact of Serum Soluble LR11 on Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter Prospective Study

Blood (2014) 124 (21): 1661.

https://doi.org/10.1182/blood.V124.21.1661.1661

Published: 2014

Journal Articles

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Yoshitaka Miyakawa, MD, PhD, Shinya Katsutani, MD, PhD, Takahiro Yano, MD, PhD, Shosaku Nomura, MD, PhD, Kaichi Nishiwaki, MD, Yoshiaki Tomiyama, MD, PhD, Masaaki Higashihara, MD, PhD, Yukari Shirasugi, MD, PhD, Masakatsu Nishikawa, MD, PhD, Katsutoshi Ozaki, MD, PhD, Kayoko Kikuchi, Takayuki Abe, PhD, Yuji Sato, MD, PhD, Yuzuru Kanakura, Kingo Fujimura, MD, PhD, Yasuo Ikeda, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 3554.

https://doi.org/10.1182/blood.V122.21.3554.3554

Published: 2013

Journal Articles

Management Of Pregnancy In Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report Of 10 Cases From The Working Group On Pregnancy Of The Japan PNH Study Group

Kensuke Usuki, MD PhD, Akio Urabe, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Naoyuki Miyasaka, MD, PhD, Osamu Miura, MD, PhD, Eriko Morishita, MD, PhD, Nobuyoshi Arima, MD, PhD, Yasuyoshi Morita, MD, PhD, Kaichi Nishiwaki, MD, Haruhiko Ninomiya, MD, PhD, Akihiko Gotoh, MD, PhD, Shinsaku Imashuku, MD, Tsutomu Shichishima, MD, PhD, Jun-ichi Nishimura, MD, PhD, Yuzuru Kanakura

Blood (2013) 122 (21): 2480.

https://doi.org/10.1182/blood.V122.21.2480.2480

Published: 2013

Journal Articles

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Eri Matsuki, MD, PhD, Takashi Kumagai, MD, Koiti Inokuchi, MD, PhD, Kazuteru Ohashi, M.D., Atsushi Shinagawa, MD, PhD, Jin Takeuchi, MD, PhD, Chikashi Yoshida, MD, PhD, Shinichiro Okamoto, MD, PhD, Hisashi Wakita, MD, Yasuji Kozai, MD, Yukari Shirasugi, MD, Shin Fujisawa, MD, Osamu Iwase, MD, Shingo Yano, MD, Kaichi Nishiwaki, MD, Koji Oba, MD, Junichi Sakamoto, MD, Hisashi Sakamaki, MD

Blood (2012) 120 (21): 691.

https://doi.org/10.1182/blood.V120.21.691.691

Published: 2012

Journal Articles

Feasibility of Reduced-Intensity Cord Blood Transplantation (RICBT) as a Salvage Therapy for Graft Failure (GF): Results of a Nationwide Survey of 63 Patients.

Blood (2006) 108 (11): 3114.

https://doi.org/10.1182/blood.V108.11.3114.3114

Published: 2006

NARROW

Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia

Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma

Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Optimal Treatment Strategy with Nilotinib for Patients with Newly Diagnosed Chronic Myelogenous Leukemia in the Chronic Phase Based on Early Achievement of Deep Molecular Response (MR 4.5 ) : First Report from N-Road, a Phase II Study in Japan

Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR 4.5 : Subgroup Analysis from STAT2 Trial in Japan

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Impact of Ph+ Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study

Impact of Serum Soluble LR11 on Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter Prospective Study

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Management Of Pregnancy In Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report Of 10 Cases From The Working Group On Pregnancy Of The Japan PNH Study Group

Relative Increase of Lymphocytes As Early As 1 Month After Initiation of Dasatinib Is a Reliable Predictor for Achieving Complete Molecular Response At 12 Months in Chronic Phase CML Patients Treated with Dasatinib

Feasibility of Reduced-Intensity Cord Blood Transplantation (RICBT) as a Salvage Therapy for Graft Failure (GF): Results of a Nationwide Survey of 63 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only